ELMSHORN, Germany, June 17 /PRNewswire/ --

- New Entry-Level Model Ready for up to 8 GB DDR2 RAM

Shuttle Inc., the market leader in the area of mini-PCs and the manufacturer of multi-form-factor solutions, is now offering another barebone for modern AMD processors. The SA76G2 hits the market with a style not unlike its predecessor, the SN68SG2: classic black G2 design in polished aluminium.

Even at only 30 x 20 x 18.5 cm (DxWxH), the compact device is the first mini-PC barebone from Shuttle to support AMD processors for socket AM3. Processors with AM2 and AM2+ sockets can also be used, ensuring maximum compatibility and long-term upgrade options. This versatility comes thanks to the AMD RS760/SB710 chipset inside.

LONDON, June 17 /PRNewswire/ --

- 85% of Consumers Aware of LBS Would Either be Prepared to Pay More for an LBS-equipped Handset (34%) or Would Choose an LBS-enabled Handset Over One Without (50%) - Top Three Location Based Services Consumers Would Adopt are Locating Nearest Services (56%), Alerting the Emergency Services to Their Location (45%) and Finding Their Friends (17%) - 68% of LBS Users Perceive Current Performance in Terms of Accuracy, Speed and Urban Effectiveness to be Average at Best

WASHINGTON, June 17 /PRNewswire/ --

- Representatives from Internet Society and Oracle elected to leadership positions as growing membership base works to bridge identity technologies, initiatives and organizations

CAMBRIDGE, Massachusetts, June 17 /PRNewswire/ --

More than half of North American households subscribe to multiplay bundles of telecom and media services, making North America the most penetrated region in the world for multiplay subscriptions, according to the recently released Multiplay Services Forecast from Pyramid Research (www.pyr.com), the telecom research arm of the Light Reading Communications Network (www.lightreading.com).

AMSTERDAM, June 17 /PRNewswire/ --

- SLA Centennial Observance Chooses 20 Elsevier Journals Among 100 Most Influential Journals in Past Century

Elsevier has been awarded the The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences at the Special Library Association's (SLA) Centennial conference on Tuesday, June 16th in Washington DC. Twenty journals published by Elsevier, many on behalf of renowned societies, were also selected as the SLA's Top 100 Journals in Biology and Medicine.

REHOVOT, Israel, June 17 /PRNewswire/ --

- Expanded System Family First to Print Multiple Materials Simultaneously

Objet Geometries (http://www.objet.com/), the innovation leader in 3D printing, today launched the Connex350(TM), the company's second rapid prototyping system that allows product developers and manufacturers to simultaneously print multiple materials with different mechanical and physical properties. Modeled after Objet's groundbreaking Connex500(TM), the only other 3D printer in the world with this capability, the Connex350(TM) will debut on June 22-26 at the inaugural Time Compression Expo and Conference in Chicago and on June 23-24 at the Devcon 2009, Dassault Systems Developer Conference in Velizy, France.

ORLANDO, Florida, June 17 /PRNewswire/ --

- Groundbreaking Sixth Generation Platform Delivers Telepresence Over General Purpose Networks, Radically Simplifying Acquisition, Deployment and Operating Costs

- Total of 130 6G Telepresence Rooms Ordered in First 30 Days of General Availability

InfoComm -- Teliris (www.teliris.com), the leading global provider of agile telepresence and collaboration, today announced it has redefined the industry with the unveiling of 6G telepresence, an affordable platform that extends an uncompromised experience to locations anywhere in the world by reducing bandwidth and related costs.

SAN JOSE, California, June 17 /PRNewswire/ --

- Compromised PCs of Individuals and Corporations are Turned Into Digital Assets That Cybercriminals Potentially Trade Online. Traded Data Also Includes About 100,000 Stolen FTP Accounts

OSLO, Norway, June 17 /PRNewswire/ --

- New Investigational Drug Also Shown to Improve Remission Rates and Reduce Short-Term Mortality Compared to Previous Treatments

Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to published clinical data for late-stage AML. Based on these encouraging results an elacytarabine registration study is being planned.